Cited by 63Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychological Treatments and Disorders

The DOI matches its Crossref record, with a small difference in title or year; 85 of the 85 references it cites were found in a registry or an index.

Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?

Olver, James S., Burrows, Graham D., Norman, Trevor R.·2001·CNS Drugs

DOI 10.2165/00023210-200115120-00004

Open this paper in CoChat — free account

Abstract

Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements. Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents.

Integrity signals

Registry

Crossref · 10.2165/00023210-200115120-00004

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
Watson, C. B., & Richelson, E. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90194-8 · Cited by 391
Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale
Bosc, M., Dubini, A., & Polin, V. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00420-3 · Cited by 370
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B. M., Nelson, A. N., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Venlafaxine
Holliday, S. M., & Benfield, P. (1995) · Drugs · doi:10.2165/00003495-199549020-00010 · Cited by 327
A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
Clerc, G. E., Ruimy, P., & Verdeau-Pailles, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 301
Once-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and Anxiety
Silverstone, P. H., Ravindran, A. V., & the Venlafaxine XR 360 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0105 · Cited by 246
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS)
Keller, M. B. (2001) · General Hospital Psychiatry · doi:10.1016/s0163-8343(00)00115-8 · Cited by 188

Show all 85 references

Research works printed but not linked: 16

Riva, 1989, J Drug Develop, 1, 243
Davis, 1996, Drugs, 5, 389
Dierick, 1996, Prog Neuropsychopharmacol Biol Psychiatry, 20, 7
Feighner, 1989, Psychopharmacol Bull, 25, 219
Fontaine, 1994, J Clin Psychiatry, 55, 234
Smith, 1990, Psychopharmacol Bull, 26, 192
Bremner, 1995, J Clin Psychiatry, 56, 519
Entsuah, 1996, Int Clin Psychopharmacol, 11, 137
Anton, 1994, Psychopharmacol Bull, 30, 165
Derivan, 1995, Psychopharmacol Bull, 31, 23
Prien, 1985, Hosp Community Psychiatry, 36, 513
Feighner, 1995, J Clin Psychiatry, 56, 574
Baldwin, 2000, Rev Contemp Pharmacother, 11, 321
Jannuzzo, 1995, Eur Neuropsychopharmacol, 5, 300
Hoes, 1996, Int Clin Psychopharmacol, 11, 147
Stormer, 2000, Drug Metab Dispos, 28, 1168

Sorted by citations

Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders
Morilak, D. A., & Frazer, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004080 · Cited by 263
New generation antidepressants for depression in children and adolescents: a network meta-analysis
Hetrick, S. E., McKenzie, J. E., Bailey, A. P., Sharma, V., Moller, C. I., Badcock, P. B., Cox, G., Merry, S., & Meader, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013674.pub2 · Cited by 218
A Double-Blind Comparison of Escitalopram and Venlafaxine Extended Release in the Treatment of Major Depressive Disorder
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Neuropeptide Y (NPY) and depression: From animal studies to the human condition
Redrobe, J. P., Dumont, Y., & Quirion, R. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02159-8 · Cited by 146
Metabolic drug interactions with new psychotropic agents
Spina, E., Scordo, M. G., & D’Arrigo, C. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00193.x · Cited by 139
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials
Hudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.696 · Cited by 116
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B. M., Brand, U., Fleischhacker, W., Goodwin, G. M., Grunze, H., Knapp, M. R. J., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 103
A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions
Sullivan, P. W., Valuck, R. J., Saseen, J. J., & MacFall, H. M. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00006 · Cited by 98
New generation antidepressants for depression in children and adolescents: a network meta-analysis
Hetrick, S. E., Meader, N., Bailey, A. P., Badcock, P. B., Moller, C. I., Cox, G., Merry, S., & McKenzie, J. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013674 · Cited by 73
Extended release of a novel antidepressant, venlafaxine, based on anionic polyamidoamine dendrimers and poly(ethylene glycol)‐containing semi‐interpenetrating networks
Yang, H., & Lopina, S. T. (2004) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30220 · Cited by 70
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
Montmorillonite-alginate microspheres as a delivery vehicle for oral extended release of Venlafaxine hydrochloride
Jain, S., & Datta, M. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2016.04.002 · Cited by 66
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants
Baumann, P., Ulrich, S., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., Rao, M. L., Riederer, P. F., Zernig, G., et al. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/pbaumann · Cited by 64
Escitalopram versus venlafaxine XR in the treatment of depression
Montgomery, S., & Andersen, H. F. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00008 · Cited by 60
The β-Endorphin Role in Stress-Related Psychiatric Disorders
Wagner, A. M., Dikshtein, Y., & Yadid, G. (2009) · Current Drug Targets · doi:10.2174/138945009789735147 · Cited by 59
Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine
Asafu-Adjaye, E. B., Faustino, P. J., Tawakkul, M. A., Anderson, L. W., Yu, L. X., Kwon, H., & Volpe, D. A. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.12.035 · Cited by 59
Limitations of current medical treatments for depression: Disturbed circadian rhythms as a possible therapeutic target
LADER, M. H. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.05.004 · Cited by 61
Controlled release of highly water-soluble antidepressant from hybrid copolymer poly vinyl alcohol hydrogels
Ali, L., Ahmad, M., Minhas, M. U., & Yousuf, M. (2013) · Polymer Bulletin · doi:10.1007/s00289-013-1043-8 · Cited by 56
Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents
Cox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48
Characterization of venlafaxine hydrochloride and compatibility studies with pharmaceutical excipients
Bernardi, L. S., de Oliveira, P. R., Murakami, F. S., Silva, M. A. S., Borgmann, S. H. M., & Cardoso, S. G. (2009) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-009-0282-2 · Cited by 45
Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites
Patel, H. A., Shah, S. S., Shah, D. O., & Joshi, P. A. (2010) · Applied Clay Science · doi:10.1016/j.clay.2010.11.013 · Cited by 43
Current approaches to management of depression in Parkinson’s Disease
Vajda, F. J. E., & Solinas, C. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2005.03.008 · Cited by 43
Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride
Jain, S., & Datta, M. (2014) · Applied Clay Science · doi:10.1016/j.clay.2014.06.006 · Cited by 42
The promises and pitfalls of reboxetine.
Page, M. (2006) · CNS drug reviews · doi:10.1111/j.1527-3458.2003.tb00258.x · Cited by 38
The treatment of depression with different formulations of venlafaxine: a comparative analysis
Olver, J. S., Burrows, G. D., & Norman, T. R. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.551 · Cited by 39
Self-citation
In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor
Aluisio, L. E., Lord, B., Barbier, A., Fraser, I. C., Wilson, S. J., Boggs, J. D., Dvorak, L. K., Letavic, M. A., Maryanoff, B. E., Carruthers, N. I., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.008 · Cited by 38
A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant
Betry, C., Overstreet, D. H., Haddjeri, N., Pehrson, A. L., Bundgaard, C., Sánchez, C., & Mørk, A. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.011 · Cited by 34
Calcium-dependent interactions of the human norepinephrine transporter with syntaxin 1A
Sung, U., & Blakely, R. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.11.007 · Cited by 35
Duloxetine Treatment of Pediatric Chronic Pain and Co-Morbid Major Depressive Disorder
Meighen, K. G. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0042 · Cited by 35
New Formulations of Existing Antidepressants
Norman, T. R., & Olver, J. S. (2004) · CNS Drugs · doi:10.2165/00023210-200418080-00003 · Cited by 29
Self-citation
Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999–2010
Soria-Saucedo, R., Liu, X., Hincapie‐Castillo, J. M., Zambrano, D. H., Bussing, R., & Winterstein, A. G. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201700260 · Cited by 27
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006
Norman, T. R., Cranston, I., Irons, J. A., Gabriel, C., Dekeyne, A., Millan, M. J., & Mocaër, E. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.010 · Cited by 26
Self-citation
Loganin ameliorates depression-like behaviors of mice via modulation of serotoninergic system
Pan, C., Xia, C., Yan, Y., Han, Y., Shi, R., He, J., Wang, Z., Wang, Y., Zhang, W., & Xu, J. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05922-8 · Cited by 24
Hippocampal MicroRNAs Respond to Administration of Antidepressant Fluoxetine in Adult Mice
Miao, N., Jin, J., Kim, S.-N., & Sun, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030671 · Cited by 19
Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity
Yin, J., Wang, W., Winston, J. H., Zhang, R., & Chen, J. D. Z. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01526.x · Cited by 19
Magnetic Solid Phase Extraction Based on Modified Magnetite Nanoparticles Coupled with Dispersive Liquid–Liquid Microextraction as an Efficient Method for Simultaneous Extraction of Hydrophobic and Hydrophilic Drugs
Jalilian, N., Asgharinezhad, A. A., Ebrahimzadeh, H., Molaei, K., & Karami, S. (2018) · Chromatographia · doi:10.1007/s10337-018-3612-3 · Cited by 17
Emerging treatments for major depression
Norman, T. R., & Burrows, G. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.203 · Cited by 17
Self-citation
Solid-state evaluation and polymorphic quantification of venlafaxine hydrochloride raw materials using the Rietveld method
Bernardi, L. S., Ferreira, F. F., Cuffini, S. L., de Campos, C. E. M., Monti, G. A., Kuminek, G., de Oliveira, P. R., & Cardoso, S. G. (2013) · Talanta · doi:10.1016/j.talanta.2013.09.006 · Cited by 15
[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans
Marthi, K., Jakobsen, S., Bender, D., Hansen, S., Smith, S., Hermansen, F., Rosenberg, R., & Smith, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1754-x · Cited by 15
Prolonged effect of the tricyclic antidepressant, mianserin on the serotonin and histamine content of young rats' white blood cells and mast cells. A case of late-imprinting
Csaba, G. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00217-2 · Cited by 14
Economic Considerations in the Prescribing of Third-Generation Antidepressants
Montgomery, S., Doyle, J., Stern, L. S., & McBurney, C. R. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00007 · Cited by 13
Comparaison de deux outils de mesure des effets indésirables d’un traitement antidépresseur : la notification spontanée et l’échelle UKU
Gruwez, B., Gury, C., Poirier, M. F., Bouvet, O., Gérard, A., Bourdel, M., Bayle, F., & Olié, J. (2004) · L Encéphale · doi:10.1016/s0013-7006(04)95457-7 · Cited by 11
Interactions between an antidepressant reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic seizures
Popławska, M., Wróblewska, D., & Borowicz, K. K. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.04.016 · Cited by 11
L’escitalopram dans le traitement des épisodes dépressifs majeurs de l’adulte
Llorca, P., Brousse, G., & Schwan, R. (2005) · L Encéphale · doi:10.1016/s0013-7006(05)82410-8 · Cited by 10
Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
Tandon, V., Gupta, B., Zargar, S., & Arora, M. (2016) · Perspectives in Clinical Research · doi:10.4103/2229-3485.173771 · Cited by 11
Are two antidepressant mechanisms better than one? Issues in clinical trial design and analysis.
Leon, A. C. (2004) · PubMed · Cited by 5
Use and impact of antidepressants in the school setting
Noggle, C. A., & Dean, R. S. (2009) · Psychology in the Schools · doi:10.1002/pits.20426 · Cited by 4
ONE FACTOR RESPONSE SURFACE METHODOLOGY (RSM) FOR THE OPTIMIZATION OF ORAL VENLAFAXINE HCL CONTROLLED RELEASE ORGANOGEL
OZA, N., Makwana, A., & Gohil, T. A. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022v14i5.45517 · Cited by 3
Newer v. older antidepressants in long-term pharmacotherapy: Revisiting… Prevention of relapse and recurrence of depression
Edwards, J. G. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.3.184 · Cited by 3
Crystal morphology prediction and experimental verification of venlafaxine hydrochloride
Liang, C., Zhuang, J., Zhuang, C., Zhang, Z., Lv, G., & Zhang, G. (2022) · Powder Diffraction · doi:10.1017/s0885715622000264 · Cited by 2
Pluronic F-68 Montmorillonite As A Drug Delivery Vehicle For Extended Release Of Venlafaxine Hydrochloride
Jain, S., & Datta, M. (2023) · Drug Research · doi:10.1055/a-2024-9964 · Cited by 2
Affective Disorders and Antidepressant Drugs
Fakhoury, M. (2014) · OALib · doi:10.4236/oalib.1100597 · Cited by 2
Für jeden Patienten den optimalen Wirkstoff finden
Lieb, M., Rupprecht, R., & Baghai, T. C. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0565-x · Cited by 2
Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting
Bukh, J. D., Jørgensen, M. B., Dam, H., & Plenge, P. (2009) · Nordic Journal of Psychiatry · doi:10.1080/08039480902799099 · Cited by 2
Study of the Effect of Eudragit RSPO on the Photostability of Venlafaxine in a Physical Mixture and in a Melt Form
Maślanka, A., Szlósarczyk, M., Talik, P., Szafraniec-Szczęsny, J., Woyna-Orlewicz, K., Żmudzki, P., & Hubicka, U. (2023) · Processes · doi:10.3390/pr11082479 · Cited by 1
The Development and Mechanism of Treatment of Depression
Chang, F., Kuang, X., & Liu, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1120 · Cited by 1
Medical management
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.004
Characterisation of the ?2A-adrenoceptor antagonism by mirtazapine and its modifying effects on receptor signalling
Khoza, K. (2004) · Boloka Institutional Repository (North-west University)
Individualized Pharmacological Treatment of Depressive Disorders State of the Art and Recent Developments
Zirngibl, C. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000154
Effects of Chronic Fluoxetine and Paroxetine Treatment on Affective Behavior of Male and Female Adolescent Rats
Harmony, Z. R. (2014) · CSUSB ScholarWorks (California State University, San Bernardino)
New antidepressant diterpenoid alkaloids from Aconitum carmichaelii Debeaux: Potential inhibitors of NLRP3 activation
Yin, W., Pan, X.-G., Bai, M.-L., Tong, Z.-H., Li, D.-X., Ding, K., He, J., Zhang, W., & Xu, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109317
Pharmacological treatment of adolescent depression: Current advances and future perspectives
Li, Y., Wang, F., Chen, G., & Zhai, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100278 · Cited by 2

Authors: Olver, J. S., Burrows, G. D., & Norman, T. R.
Affiliations: The University of Melbourne (AU)
Corresponding author: Norman, Trevor R.
ORCID: Norman, Trevor R.
Venue: CNS Drugs
Publisher: Springer Science and Business Media LLC
Published: 2001
Volume: 15
Issue: 12
Pages: 941-954
ISSN: 1172-7047 (ISSN-L)
DOI: 10.2165/00023210-200115120-00004
OpenAlex: W2087328751
Cited by: 63
References: 85
Citations by year: 2025: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2018: 3 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
FWCI: 0.56
Type: journal article
Language: en
Open access: closed
Locations: CNS Drugs (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords: venlafaxine, reboxetine, nefazodone, mirtazapine, depression, selective serotonin reuptake inhibitors, antidepressant efficacy, relapse prevention, onset of action, drug safety
MeSH terms: Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Humans, Selective Serotonin Reuptake Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks